Monitoring to prevent transplant rejection

Transplant Genomics focuses on enhancing organ transplant outcomes through innovative noninvasive diagnostic technologies that leverage genetic biomarkers. Their molecular diagnostic tests, such as TruGraf and TRAC, are designed to detect early signs of graft injury and differentiate between various causes of rejection. TruGraf, for instance, utilizes gene expression profiling to monitor the immune state of transplant recipients, ensuring adequate immunosuppression and identifying potential subclinical rejection. This approach allows for timely interventions, optimizing therapy and improving patient management post-transplant.

Additionally, Transplant Genomics employs advanced techniques like the analysis of donor-derived cell-free DNA (dd-cfDNA) to assess organ health. This method provides a noninvasive means to measure organ injury by distinguishing between the DNA from the transplant and that of the recipient. By integrating these genomic insights into clinical practice, the company aims to refine the monitoring of transplant patients, enabling personalized care and better long-term outcomes. Their commitment to precision medicine is evident in their focus on developing tools that facilitate early detection of complications and inform treatment decisions.

United States

Transplant Genomics is a biotechnology company that focuses on improving organ transplant outcomes through noninvasive serial monitoring driven by genomics.

Transplant Genomics

Company Details